MTOR and neuroblastoma: To determine how R+D ‘pre-treatment’ with Rapamycin plus Dasatinib (R+D) affects the neoplastic signaling response, the mammalian Target of Rapamycin (mTOR) signaling pathway and phosphorylation of the Src kinase family were assessed in NB monolayer and spheroid cultures.